Showing 3 posts of 3 posts found.

FDA fast track designation for Biogen’s investigational Alzheimer’s treatment

September 2, 2016
Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track

Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …

Alzheimer's research

Neurimmune kicks off late-stage Alzheimer’s study

September 9, 2015
Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology

Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab.  The …

Biogen image

Biogen shortens name and posts positive Alzheimer’s results

March 23, 2015
Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec

Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …

Latest content